Your browser is no longer supported. Please, upgrade your browser.
Settings
ECYT Endocyte, Inc. daily Stock Chart
ECYT [NASD]
Endocyte, Inc.
Index- P/E- EPS (ttm)-1.35 Insider Own2.60% Shs Outstand39.72M Perf Week0.00%
Market Cap188.67M Forward P/E- EPS next Y-0.91 Insider Trans0.55% Shs Float39.06M Perf Month0.00%
Income-57.60M PEG- EPS next Q-0.16 Inst Own37.20% Short Float6.49% Perf Quarter265.38%
Sales0.07M P/S2695.29 EPS this Y-5.70% Inst Trans-20.09% Short Ratio0.81 Perf Half Y88.49%
Book/sh2.39 P/B1.99 EPS next Y26.60% ROA-45.60% Target Price7.00 Perf Year56.25%
Cash/sh2.60 P/C1.83 EPS next 5Y- ROE-47.80% 52W Range1.17 - 6.55 Perf YTD86.27%
Dividend- P/FCF- EPS past 5Y5.70% ROI- 52W High-27.48% Beta2.22
Dividend %- Quick Ratio24.00 Sales past 5Y- Gross Margin- 52W Low305.98% ATR0.39
Employees76 Current Ratio24.00 Sales Q/Q0.00% Oper. Margin- RSI (14)56.14 Volatility7.01% 8.41%
OptionableYes Debt/Eq0.00 EPS Q/Q-164.90% Profit Margin- Rel Volume0.20 Prev Close4.84
ShortableYes LT Debt/Eq0.00 EarningsNov 06 AMC Payout- Avg Volume3.12M Price4.75
Recom2.00 SMA200.15% SMA5022.19% SMA20096.10% Volume629,608 Change-1.86%
Oct-03-17Upgrade Wedbush Neutral → Outperform $2 → $7
Jun-05-17Downgrade Wedbush Outperform → Neutral $8 → $2
Mar-03-16Reiterated Wedbush Outperform $12 → $8
Jan-21-16Initiated Credit Suisse Outperform
Nov-04-15Reiterated RBC Capital Mkts Outperform $13 → $10
Aug-05-15Reiterated RBC Capital Mkts Outperform $15 → $13
Sep-30-14Downgrade Brean Capital Buy → Hold
Jul-08-14Resumed Brean Capital Buy $22
Jun-18-14Reiterated RBC Capital Mkts Outperform $20 → $15
Jun-18-14Reiterated Chardan Capital Markets Buy $26 → $15
May-05-14Reiterated RBC Capital Mkts Outperform $46 → $20
May-05-14Reiterated Chardan Capital Markets Buy $43 → $26
May-02-14Reiterated Brean Capital Buy $41 → $22
May-02-14Downgrade Robert W. Baird Outperform → Neutral $36 → $8
Mar-25-14Reiterated Chardan Capital Markets Buy $20 → $43
Mar-21-14Reiterated Brean Capital Buy $21 → $41
Sep-30-13Initiated Chardan Capital Markets Buy $20
Mar-25-13Upgrade Robert W. Baird Neutral → Outperform $9 → $13
Dec-21-12Reiterated RBC Capital Mkts Outperform $12 → $15
Nov-20-12Initiated Summer Street Research Buy $18
Nov-21-17 11:40AM  ETFs with exposure to Endocyte, Inc. : November 21, 2017 Capital Cube
Nov-09-17 04:01PM  Endocyte to Present at the Jefferies 2017 London Healthcare Conference GlobeNewswire +9.28%
07:18AM  Edited Transcript of ECYT earnings conference call or presentation 6-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-07-17 09:19AM  Endocyte (ECYT) Posts Narrower-than-Expected Q3 Loss Zacks
Nov-06-17 04:09PM  Endocyte reports 3Q loss Associated Press
04:01PM  Endocyte Reports Third Quarter Financial Results GlobeNewswire
07:25AM  Endocyte, Inc. to Host Earnings Call ACCESSWIRE
Oct-31-17 11:49AM  Will Endocyte (ECYT) Disappoint This Earnings Season? Zacks
Oct-30-17 04:01PM  Endocyte Announces Third Quarter 2017 Earnings Conference Call GlobeNewswire
Oct-18-17 11:59AM  Why Endocyte Is Rallying Today Motley Fool +12.87%
Oct-10-17 08:31AM  Endocyte, Wedbush Analyst Upgrade, and the PSMA-617 Licensing Deal ACCESSWIRE
Oct-09-17 10:13AM  Cancer Space Last Week Update: Pipeline Expansion in Focus Zacks -9.74%
Oct-07-17 10:34AM  3 Drug Stocks That Soared This Week: Are They Buys? Motley Fool
Oct-04-17 07:54AM  Biotech Stock Roundup: Endocyte Shoots up on Deal, Amgen-AbbVie Settle Humira Litigation Zacks
Oct-03-17 04:58PM  Endocyte Inks Deal For Prostate Cancer Candidate, Shares Up Zacks +61.98%
02:36PM  Endocyte's stock rockets again on heavy volume after license deal for prostate cancer treatment MarketWatch
01:58PM  Why Endocyte, Inc. (ECYT) Stock Is Going Bonkers Today InvestorPlace
11:10AM  ETFs with exposure to Endocyte, Inc. : October 3, 2017 Capital Cube
09:00AM  Options Traders Expect Huge Moves in Endocyte (ECYT) Stock Zacks
08:20AM  Today's Research Reports on Stocks to Watch: Endocyte and INSYS Therapeutics ACCESSWIRE
Oct-02-17 04:40PM  Closing Bell; Endocyte Spikes: LIVE MARKETS BLOG TheStreet.com +157.45%
07:30AM  Endocyte Announces Exclusive Worldwide License of Phase 3 Ready PSMA-Targeted Radioligand Therapy for Development in Prostate Cancer GlobeNewswire
Sep-27-17 07:15PM  Bottom Fishing With Cash-Rich Biotechs GuruFocus.com
Sep-19-17 04:01PM  Endocyte to Present at the 2017 Cantor Global Healthcare Conference GlobeNewswire
Sep-06-17 08:00AM  Endocyte Presents Data at the 2017 CAR-TCR Summit Further Demonstrating the Ability to Manage Cytokine Release Syndrome Related to CAR T-Cell Therapy GlobeNewswire
Sep-05-17 04:01PM  Endocyte Announces Presentation at the European Society for Medical Oncology (ESMO) GlobeNewswire
Aug-31-17 06:14PM  ETFs with exposure to Endocyte, Inc. : August 31, 2017 Capital Cube
Aug-24-17 10:17AM  Endocyte, Inc. :ECYT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-16-17 04:20PM  Edited Transcript of ECYT earnings conference call or presentation 8-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
08:00AM  Endocyte Announces Presentations at the 254th American Chemical Society National Meeting & Exposition GlobeNewswire
Aug-10-17 01:07AM  Endocyte reports 2Q loss Associated Press
Aug-09-17 10:53AM  Endocyte (ECYT) Stock Up Despite Wider-than-Expected Q2 Loss Zacks
Aug-08-17 04:01PM  Endocyte Reports Second Quarter Financial Results and Provides Clinical and Pipeline Update GlobeNewswire
10:10AM  Investor Network: Endocyte, Inc. to Host Earnings Call ACCESSWIRE
Aug-04-17 10:07AM  Spectrum (SPPI) Q2 Loss Narrower than Expected, Sales Beat Zacks
09:47AM  Shire (SHPG) Beats on Q2 Earnings & Sales, Updates '17 View Zacks
Aug-01-17 04:01PM  Endocyte Announces Second Quarter 2017 Earnings Conference Call GlobeNewswire
Jul-26-17 10:59AM  What's in Store for Endocyte (ECYT) this Earnings Season? Zacks
Jul-13-17 10:36AM  Endocyte (ECYT) to Focus on Promising CAR-T Cell Platform Zacks
Jun-20-17 02:53PM  ETFs with exposure to Endocyte, Inc. : June 20, 2017 Capital Cube
Jun-14-17 06:06AM  Why Is Endocyte (ECYT) Down 37.9% Since the Last Earnings Report? Zacks
Jun-05-17 02:13PM  ETFs with exposure to Endocyte, Inc. : June 5, 2017 Capital Cube -7.85%
Jun-02-17 09:36AM  Endocyte, Inc. :ECYT-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube -30.04%
08:42AM  Endocyte stock plummets 30% on news of major workforce reduction; clinical trial changes MarketWatch
08:02AM  Endocyte Announces Clinical Updates for EC1456 and EC1169 GlobeNewswire
May-31-17 08:15AM  Blog Coverage: Endocyte to Present Posters on its Lead Clinical Stage Assets at the ASCO Annual Meeting Accesswire -6.59%
08:00AM  Today's Research Reports on Stocks to Watch: Endocyte and CytRx Accesswire
May-26-17 04:01PM  Endocyte to Announce Updated Data on EC1456 and EC1169 at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-18-17 05:10PM  Endocyte (ECYT) Focused on Two Lead Pipeline Candidates Zacks -5.34%
May-15-17 03:10PM  Edited Transcript of ECYT earnings conference call or presentation 10-May-17 12:30pm GMT Thomson Reuters StreetEvents
08:00AM  Today's Research Reports on Stocks to Watch: Globalstar and Endocyte Accesswire
May-11-17 08:18AM  Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q1 Zacks
May-10-17 09:06PM  Edited Transcript of ECYT earnings conference call or presentation 10-May-17 12:30pm GMT Thomson Reuters StreetEvents +10.27%
09:33AM  Endocyte (ECYT) Reports Narrower than Expected Q1 Loss Zacks
08:22AM  Endocyte reports 1Q loss Associated Press
08:00AM  Endocyte Reports First Quarter Financial Results and Provides Clinical and Pipeline Update GlobeNewswire
07:45AM  Investor Network: Endocyte, Inc. to Host Earnings Call Accesswire
May-03-17 04:01PM  Endocyte Announces First Quarter 2017 Earnings Conference Call GlobeNewswire
May-01-17 04:03PM  What to Expect from Endocyte (ECYT) Stock for Q1 Earnings? Zacks
Apr-12-17 02:05PM  Screening for Net-Net Stocks in an Overvalued Market GuruFocus.com
Apr-10-17 07:10AM  Endocyte (ECYT) Up 3.5% Since Earnings Report: Can It Continue? Zacks
Apr-05-17 08:00AM  Endocyte Presents Data at AACR Identifying Multiple Methods for Managing Severe Side Effects Resulting from CAR T-Cell Treatment GlobeNewswire
08:00AM  Endocyte Presents Data at AACR Identifying Multiple Methods for Managing Severe Side Effects Resulting from CAR T-Cell Treatment
Mar-27-17 04:01PM  Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2017 GlobeNewswire
Mar-21-17 11:29AM  Endocyte, Inc. :ECYT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Capital Cube -8.33%
11:29AM  Endocyte, Inc. :ECYT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
Mar-17-17 01:04PM  ENDOCYTE INC Financials
Mar-16-17 09:23AM  5 Cheap Breakout Stocks for Superb Returns Zacks
09:23AM  5 Cheap Breakout Stocks for Superb Returns
Mar-15-17 01:55PM  Endocyte, Inc. :ECYT-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Capital Cube
01:55PM  Endocyte, Inc. :ECYT-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
Mar-14-17 06:16PM  Endocyte (ECYT) Reports Wider-than-Expected Loss in Q4 Zacks -7.25%
06:16PM  Endocyte (ECYT) Reports Wider-than-Expected Loss in Q4
10:16AM  Endocyte (ECYT) Shares March Higher, Can It Continue? Zacks
10:16AM  Endocyte (ECYT) Shares March Higher, Can It Continue?
Mar-13-17 04:23PM  ENDOCYTE INC Files SEC form 10-K, Annual Report +7.38%
Mar-12-17 09:09PM  Edited Transcript of ECYT earnings conference call or presentation 10-Mar-17 1:30pm GMT Thomson Reuters StreetEvents
09:09PM  Edited Transcript of ECYT earnings conference call or presentation 10-Mar-17 1:30pm GMT
Mar-10-17 08:52AM  Endocyte (ECYT) Reports a Wider Q4 Loss Zacks +7.49%
08:52AM  Endocyte (ECYT) Reports a Wider Q4 Loss
08:20AM  Endocyte reports 4Q loss
08:16AM  ENDOCYTE INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial S
08:05AM  Endocyte Reports Fourth Quarter and Year End 2016 Financial Results and Provides Clinical and Pipeline Update GlobeNewswire
08:00AM  Endocyte and Seattle Childrens Research Institute to Collaborate on Endocytes Small Molecule Drug Conjugate Bi-Specific Adaptor Molecules for CAR T-cell Therapies GlobeNewswire
Mar-02-17 08:00AM  Endocyte Announces Fourth Quarter and Full Year 2016 Earnings Conference Call GlobeNewswire
Mar-01-17 04:01PM  Endocyte to Present at the Cowen and Company 37th Annual Health Care Conference GlobeNewswire +10.24%
Feb-23-17 04:43PM  Endocyte (ECYT) to Post Q4 Earnings: What's in the Cards?
Feb-21-17 04:07PM  ENDOCYTE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
08:00AM  Endocyte Appoints Michael T. Andriole as Chief Financial Officer GlobeNewswire
Jan-11-17 04:42PM  Valeant Streamlines Portfolio with Skincare Brands Sale
Jan-10-17 09:49AM  Valeant to Sell Dendreon Unit to Sanpower for $820 Million
Jan-03-17 03:22PM  Is Valeant (VRX) Fated for Terrible 2017 As Well?
Dec-15-16 09:08PM  How Endocyte, Inc. (ECYT) Stacks Up Against Its Peers at Insider Monkey
Dec-14-16 12:59PM  ETFs with exposure to Endocyte, Inc. : December 14, 2016
Dec-05-16 03:00AM  Mission Therapeutics Appoints Colin Goddard as Chairman PR Newswire
Dec-01-16 08:01AM  Endocyte to Present at the IASLC 17th World Conference on Lung Cancer GlobeNewswire
Nov-29-16 03:10PM  ETFs with exposure to Endocyte, Inc. : November 29, 2016
Nov-28-16 10:54AM  Endocyte, Inc. :ECYT-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 -6.67%
Nov-11-16 08:08AM  Endocyte (ECYT) Stock Up on Lower-than-Expected Q3 Loss
Nov-09-16 04:46PM  Endocyte reports 3Q loss +6.47%
Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Low Philip SChief Science OfficerNov 13Buy4.845,60027,104288,605Nov 14 03:26 PM
Sherman Michael A.President, CEO and CFOMay 31Option Exercise2.1044,28592,999208,111Jun 02 08:14 AM
Leamon Christopher PVice President of ResearchDec 30Option Exercise2.1026,17854,97490,227Jan 04 04:44 PM
Leamon Christopher PVice President of ResearchDec 30Sale2.5523,24459,27266,983Jan 04 04:44 PM